Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Pyxis Oncology (NASDAQ:PYXS) released its quarterly earnings data on Monday. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.01, Zacks reports.

Pyxis Oncology Price Performance

Shares of PYXS stock remained flat at $3.90 during trading on Wednesday. 77,882 shares of the company traded hands, compared to its average volume of 613,346. The firm has a market cap of $241.87 million, a PE ratio of -2.44 and a beta of 1.40. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.39. The business’s 50 day simple moving average is $2.57 and its 200-day simple moving average is $1.66.

Institutional Investors Weigh In On Pyxis Oncology

A number of large investors have recently made changes to their positions in PYXS. Bridgeway Capital Management LLC lifted its stake in shares of Pyxis Oncology by 76.1% in the 2nd quarter. Bridgeway Capital Management LLC now owns 142,295 shares of the company’s stock valued at $157,000 after purchasing an additional 61,500 shares during the period. Jane Street Group LLC purchased a new position in shares of Pyxis Oncology in the second quarter worth $370,000. Qube Research & Technologies Ltd raised its stake in shares of Pyxis Oncology by 128.4% in the second quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company’s stock worth $113,000 after purchasing an additional 57,935 shares during the last quarter. Marshall Wace LLP purchased a new stake in Pyxis Oncology during the second quarter valued at $163,000. Finally, XTX Topco Ltd purchased a new stake in Pyxis Oncology during the second quarter valued at $40,000. 39.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PYXS has been the topic of a number of research analyst reports. Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research note on Monday. They issued a “buy” rating and a $9.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. Guggenheim upped their price target on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Pyxis Oncology in a research report on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.40.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.